
Kheiron, now operating as DeepHealth, is a world leader in AI-powered health informatics for radiology, specifically focused on earlier cancer detection. Their flagship product, Mia, is an AI solution for breast cancer screening that empowers doctors to deliver more confident and accurate results, assisting in crucial decisions about patient follow-up. Clinical studies show Mia can detect 13% more cancers and potentially halve missed diagnoses, saving thousands of lives annually. The company was founded by individuals from medical families, driven by a mission to improve cancer care through AI, and has been recognized in major publications like Nature Medicine and The New York Times.

Kheiron, now operating as DeepHealth, is a world leader in AI-powered health informatics for radiology, specifically focused on earlier cancer detection. Their flagship product, Mia, is an AI solution for breast cancer screening that empowers doctors to deliver more confident and accurate results, assisting in crucial decisions about patient follow-up. Clinical studies show Mia can detect 13% more cancers and potentially halve missed diagnoses, saving thousands of lives annually. The company was founded by individuals from medical families, driven by a mission to improve cancer care through AI, and has been recognized in major publications like Nature Medicine and The New York Times.
Founded: 2016
Headquarters: London, UK
Flagship product: Mia — AI for breast cancer screening
Clinical evidence: Peer-reviewed publications including Nature Medicine
Notable investor: Atomico (Series A lead)
Breast cancer screening and radiology diagnostics
2016
Data and Analytics
$22,000,000
Atomico led the round with participation from Connect Ventures, Entrepreneur First, Greycroft, Hoxton Ventures and EXOR Seeds.
Crunchbase lists a later round classified as a Convertible Note.
“Has participation from well-known VCs (Atomico lead Series A) and multiple institutional investors”